Cost-effectiveness models for Alzheimer’s disease and related dementias: IPECAD modelling workshop cross comparison challenge

INTRODUCTION: The credibility of model-based economic evaluations of Alzheimer’s disease (AD) interventions is central to appropriate decision-making in a policy context. We report on the International PharmacoEconomic Collaboration on Alzheimer’s Disease (IPECAD) Modelling Workshop Challenge. METHODS: Two common benchmark scenarios, for the hypothetical treatment of AD mild cognitive impairment (MCI) and mild dementia, were jointly developed by 29 participants. Model outcomes were summarized, and cross-comparisons were discussed during a structured workshop. RESULTS: A broad concordance was established among participants. Mean 10-year restricted survival and time in MCI in control group ranged across 10 MCI models from 6.7-9.5 years and 3.4-5.6 years, respectively; and across 4 mild dementia models from 5.4-7.9 (survival) and 1.5-4.2 (mild dementia). DISCUSSION: The model comparison increased our understanding of methods, data used, and disease progression. We established a collaboration framework to assess cost-effectiveness outcomes, an important step towards transparent and credible AD models